Press "Enter" to skip to content

AstraZeneca in cancer drug deal that could pay Daiichi Sankyo up to $6.9 billion

TOKYO (Reuters) – AstraZeneca Plc and Daiichi Sankyo Co Ltd signed a deal to develop and sell Daiichi’s cancer drug trastuzumab deruxtecan that could see the British drugmaker pay as much as $6.9 billion to its Japanese partner.

FILE PHOTO: A sign is seen at an AstraZeneca site in Macclesfield, central England May 19, 2014. REUTERS/Phil Noble/File Photo

The news sent Daiichi’s shares soaring 16 percent, its daily limit, to a record early on Friday. Daiichi’s stock has climbed 45 percent this year on optimism about the drug.

Under the deal, AstraZeneca will make an upfront payment of $1.35 billion to Daiichi. They will share development and commercialization costs for the drug worldwide, with Daiichi retaining exclusive rights in Japan.

“My impression is the upfront payment is particularly large. It’s a sign that AstraZeneca assumes the drug will become mainstream in the next generation,” said Takashi Akahane, a senior analyst at Tokai Tokyo Research Center.

Daiichi is the latest Japanese drugmaker to strike a deal to gain access to a bigger overseas player’s R&D and sales clout.

The deal is also a big bet on Japanese research by AstraZeneca Chief Executive Pascal Soriot, who is seeing results in his efforts to replenish the British drugmaker’s pipeline as its cancer drug sales grow.

The two drugmakers have a long-standing relationship which includes a 2015 agreement to jointly commercialize constipation drug Movantik in the United States.

Trastuzumab deruxtecan “could become a transformative new medicine for the treatment of HER2 positive breast and gastric cancers”, Soriot said in a statement.

The drug also has the potential to treat lung and colorectal cancers. AstraZeneca plans to use some of the proceeds of a $3.5 billion share issue to fund the deal.

The treatment, called antibody-drug conjugate (ADC), is designed to attack only cancer cells while sparing the healthy cells that are usually damaged during typical chemotherapy treatments.

Roche Holding AG’s Kadcyla, also an ADC for HER2-positive breast cancer, won U.S. Food and Drug Administration (FDA) approval in 2013.

Daiichi is expected to book sales for the cancer drug in the United States, certain countries in Europe and some other markets where it has affiliates.

AstraZeneca is expected to book sales in all other markets worldwide, including China, Australia, Canada and Russia.

Daiichi has declared in its long-term vision to focus on oncology, targeting 500 billion yen ($4.52 billion) in annual sales from the business in fiscal 2025, from 20 billion in 2017.

The Japanese drugmaker is exploring the sale of its over-the-counter drugs business and has hired JPMorgan to advise on the potential deal, Reuters has reported.

In a separate statement on Friday, Daiichi said its President and Chief Operating Officer, Sunao Manabe, would replace George Nakayama as CEO, effective June 17. It did not give a reason for the change.

Reporting by Sam Nussey and Takashi Umekawa in Tokyo; Additional reporting by Bhargav Acharya in Bengaluru; Editing by Sandra Maler and Muralikumar Anantharaman

Our Standards:The Thomson Reuters Trust Principles.